Why is Ionis Pharmaceuticals stock down 4.7% today?
Ionis Pharmaceuticals (IONS) dropped 4.74% after investors reacted to data showing its therapy pelacarsen did not meet the primary endpoint in the HORIZON cardiovascular trial, even as positive phase 3 results for ulefnersen in ALS were announced. The down move is supported by bearish technicals, with IONS trading below its key moving averages and oversold momentum indicators confirming persistent selling interest.
Highlights
- Ionis Pharmaceuticals announced positive phase 3 data from the FUSION study, showing clinical benefit for ulefnersen in ALS patients.
- Pelacarsen did not meet its primary endpoint in the HORIZON trial for cardiovascular risk, and shares remain under broad selling pressure despite ongoing licensing and partnership revenues.
- Ionis Pharmaceuticals stock trades below key moving averages with technical signals showing oversold conditions and a forecasted range of $42.11 to $46.5 over the next five days.
Ongoing selling pressure as positive ALS data contrasts with trial miss
Ionis Pharmaceuticals released positive phase 3 results from the FUSION study, showing meaningful clinical benefit for ulefnersen in ALS patients. The company also reported that pelacarsen failed to meet its primary endpoint in the HORIZON trial targeting cardiovascular risk. Ionis continued to highlight partnerships and licensing activities for revenue generation, though price action has remained under broader selling pressure.
Downward momentum persists as all technicals point to weakness
IONIS trades below its 20-day ($54.82), 50-day ($55.49), and 200-day ($71.82) moving averages, indicating persistent downward momentum across all timeframes. The alignment of the 50-day and 200-day averages confirms a bearish structure. Resistance is at $44.28 and support is at $42.11. Momentum remains weak, as MACD and ADX signal a sell bias. The RSI at 29.71 and CCI at -113.32 show oversold conditions, while BBP at -3.94 and the negative Awesome Oscillator reading reinforce the dominance of sellers. Today's session opened with a downside gap and the stock is trading near its low, with intraday volatility at 3.50%. A modest technical divergence is present as the Hull Moving Average gives a buy signal, but all other core indicators remain bearish.
Previously it was reported that Ionis Pharmaceuticals was exhibiting persistent technical weakness amid dominant bearish momentum. The latest developments reinforce that downside risk remains elevated, making $42.11 a critical support level for traders to monitor in the near term.